COMPOSITION AND FORM OF RELEASE

The Purvax RCPCh vaccine contains: an attenuated strain of the feline infectious rhinotracheitis virus FHV F2, a combination of two inactivated strains of the feline calicivirus virus FCV 431 and FCV G1, an attenuated strain of the feline panleukopenia virus PLI IV and an attenuated strain of feline chlamydia 905.
It is a lyophilized, dry, homogeneous, porous mass of white color. The vaccine is packaged in glass vials of 1 dose and packed in plastic boxes containing 10 vials of vaccine (10 doses) and 10 vials of solvent of 1 ml. PHARMACOLOGICAL PROPERTIES

The Purvax RCPCh vaccine induces reliable protective immunity in vaccinated cats after 2 weeks against panleukopenia and chlamydia and after 4 weeks against rhinotracheitis and calicivirus infection after repeated vaccination. The intensity of immunity is sufficient to ensure a high level of antibodies to rhinotracheitis, calicivirus, panleukopenia and chlamydia in cats for 12 months after vaccination.
The vaccine is harmless and areactogenic.

INDICATIONS

It is prescribed to cats to create active immunity against viral rhinotracheitis, calicivirus infection, panleukopenia and chlamydia.

DOSAGE AND ADMINISTRATION

Only clinically healthy animals are subject to vaccination. The injection site is not treated. A sterile needle is used for each animal. Immediately before use, 1 ml of solvent is added to the vaccine vial using a sterile syringe and shaken thoroughly until a homogeneous suspension is formed. The vaccine is administered to the animal subcutaneously in the shoulder blade area in the amount of one dose (1 ml), regardless of the weight and breed of the cat. Cats are recommended to be vaccinated from the age of 8 weeks. Primary vaccination is carried out twice with an interval of 3 - 4 weeks. In the presence of high titers of specific maternal antibodies, primary vaccination is postponed until the animal reaches 12 weeks of age. Animals are revaccinated in the same dose once a year. It is recommended to vaccinate all susceptible animals in the same room at the same time.

SIDE EFFECTS

Cats sometimes experience increased drowsiness, decreased appetite, or increased body temperature for 1–2 days. Some animals may experience a local reaction in the form of a painful lump, itching, or local swelling after the vaccine has been administered, which spontaneously disappears after 1–2 weeks. In case of hypersensitivity reactions, symptomatic treatment is indicated.

CONTRAINDICATIONS

Hypersensitivity to vaccine components. Pregnant and lactating animals, as well as sick animals, suspected of having the disease, non-dewormed, and exhausted animals should not be vaccinated. The vaccine should not be used simultaneously with other immunobiological preparations, with the exception of the rabies vaccine "Rabizin".

SPECIAL INSTRUCTIONS

Vials with the vaccine without labels, with damaged packaging and closure, frozen, with a changed color and consistency, containing foreign impurities, as well as those not used within 20 minutes after dilution are subject to rejection and disinfection by boiling for 5-10 minutes, followed by disposal. The Purvax vaccine can be used simultaneously with the Rabizin rabies vaccine, provided that they are administered separately. Other vaccines can be prescribed 14 days before or after the use of Purvax RCPCh.

STORAGE CONDITIONS

Store and transport in a dry place protected from light and inaccessible to children and animals at a temperature of 2 to 8 ºС. Freezing of the vaccine is not allowed. Shelf life is 18 months.

MANUFACTURER

Merial S.A.S. (Merial S.A.S.), France.